SMARCA4: Current status and future perspectives in non-small-cell lung cancer

被引:38
|
作者
Tian, Yumeng [1 ]
Xu, Lu [1 ]
Li, Xin [1 ]
Li, Heming [1 ,2 ]
Zhao, Mingfang [1 ,2 ]
机构
[1] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang 110001, Peoples R China
[2] China Med Univ, Hosp 1, Dept Med Oncol, 155 Nanjingbei Rd, Shenyang 110001, Liaoning, Peoples R China
关键词
NSCLC; SMARCA4; gene; SMARCA2; SWI/SNF complex; Immunotherapy; CHROMATIN-REMODELING FACTOR; TUMOR-SUPPRESSOR; SYNTHETIC LETHAL; SWI/SNF COMPLEX; CLINICOPATHOLOGICAL CHARACTERISTICS; DOWN-REGULATION; BAF COMPLEXES; DNA-DAMAGE; BRG1; MUTATIONS;
D O I
10.1016/j.canlet.2022.216022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
SMARCA4, also known as transcription activator, is an ATP-dependent catalytic subunit of SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that participates in the regulation of chromatin structure and gene expression by supplying energy. As a tumor suppressor that has aberrant expression in similar to 10% of non-small-cell lung cancers (NSCLCs), SMARCA4 possesses many biological functions, including regulating gene expression, differentiation and transcription. Furthermore, NSCLC patients with SMARCA4 alterations have a weak response to conventional chemotherapy and poor prognosis. Therefore, the mechanisms of SMARCA4 in NSCLC development urgently need to be explored to identify novel biomarkers and precise therapeutic strategies for this subtype. This review systematically describes the biological functions of SMARCA4 and its role in NSCLC development, metastasis, functional epigenetics and potential therapeutic approaches for NSCLCs with SMARCA4 alterations. Additionally, this paper explores the relationship and regulatory mechanisms shared by SMARCA4 and its mutually exclusive catalytic subunit SMARCA2. We aim to provide innovative treatment strategies and improve clinical outcomes for NSCLC patients with SMARCA4 alterations.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Molecular Characteristics of SMARCA4 Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients
    Chen, X.
    Xu, C.
    Wang, W.
    Zhuang, W.
    Song, Z.
    Zhu, Y.
    Chen, R.
    Guan, Y.
    Yi, X.
    Chen, Y.
    Chen, G.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1945 - S1945
  • [22] Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
    Qu, Jingjing
    Mei, Quanhui
    Chen, Lijun
    Zhou, Jianying
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 619 - 631
  • [23] Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
    Jingjing Qu
    Quanhui Mei
    Lijun Chen
    Jianying Zhou
    Cancer Immunology, Immunotherapy, 2021, 70 : 619 - 631
  • [24] A Critical Review of the Impact of SMARCA4 Mutations on Survival Outcomes in Non-Small Cell Lung Cancer
    Manolakos, Peter
    Boccuto, Luigi
    Ivankovic, Diana S.
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [25] SMARCA4 alterations in non-small cell lung cancer: a systematic review and meta-analysis
    Wankhede, Durgesh
    Grover, Sandeep
    Hofman, Paul
    JOURNAL OF CLINICAL PATHOLOGY, 2024, 77 (07) : 457 - 463
  • [26] To treat or not to treat non-small-cell lung cancer patients? Current perspectives
    Bunn, PA
    ONCOLOGY-NEW YORK, 1999, 13 (09): : 9 - 15
  • [27] Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer
    Mondelo-Macia, Patricia
    Garcia-Gonzalez, Jorge
    Leon-Mateos, Luis
    Castillo-Garcia, Adrian
    Lopez-Lopez, Rafael
    Muinelo-Romay, Laura
    Diaz-Pena, Roberto
    BIOMEDICINES, 2021, 9 (01) : 1 - 22
  • [28] Current and future strategies for Antiangiogenic agents in non-small-cell lung cancer
    Herbst, Roy S.
    CLINICAL LUNG CANCER, 2008, 9 : S50 - S50
  • [29] Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods
    Zarogoulidis, Paul
    Kosmidis, Christoforos
    Fyntanidou, Varvara
    Aidoni, Zoi
    Tsakiridis, Kosmas
    Koulouris, Charilaos
    Michalopoulos, Nikolaos
    Barmpas, Anastasios
    Huang, Haidong
    Bai, Chong
    Hohenforst-Schmidt, Wolfgang
    Sapalidis, Konstantinos
    LUNG CANCER MANAGEMENT, 2019, 8 (03)
  • [30] EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
    Hou, Jiabao
    Li, Hongle
    Ma, Shuxiang
    He, Zhen
    Yang, Sen
    Hao, Lidan
    Zhou, Hanqiong
    Zhang, Zhe
    Han, Jing
    Wang, Li
    Wang, Qiming
    BIOMARKER RESEARCH, 2022, 10 (01)